Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

NCT05994365 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT05994365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05994365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Observational
Overall status
Recruiting
Start date
August 31, 2023
Completion date
December 31, 2028
Enrollment
380 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid neoplasms